KPKlaus Pietzner

Klaus Pietzner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Klaus Pietzner has a total of 215 co-authors. Here are the top co-authors by number of shared publications:

  • Jalid Sehouli

    Department of Gynecology with Center for Oncological Surgery, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany

    20 shared publications
  • Jalid Sehouli

    European Competence Center for Ovarian Cancer, Charité Berlin, Department of Gynecology with Center for Oncological Surgery, Berlin, Germany

    9 shared publications
  • Radoslav Chekerov

    NOGGO and Department of Gynecology, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany

    5 shared publications
  • Christina Fotopoulou

    Department of Surgery and Cancer Imperial College London London UK

    4 shared publications
  • Radoslav Chekerov

    European Competence Center for Ovarian Cancer, Charité Berlin, Department of Gynecology with Center for Oncological Surgery, Berlin, Germany

    4 shared publications
  • Dario Zocholl

    European Competence Center for Ovarian Cancer, Charité Berlin, Department of Gynecology with Center for Oncological Surgery, Berlin, Germany

    3 shared publications

Latest Publications

  • Open Access

    Clinical relevance of CA125 in low-grade serous ovarian cancer: a retrospective multi-center JAGO/NOGGO study

    by Chiara Flethe, Mina Netkova-Heintzen, Magdalena Postl, Laura Tascón Padrón, Christina Tauber, Elisa Sieghartsleitner, Maximilian Pruss, Matthias Kohlen, Annette Aigner, Christina Grech, et al.

  • Open Access

    The implementation of frailty assessment in gynecologic oncology: an international multicenter JAGO-NOGGO survey

    by C. Flethe, C. Krause, A. von Beckerath, S. Alavi-Demirci, G. Kolb, M. Beck, K. Pietzner, J. Sehouli

    Purpose: The global aging trend is expected to double the population aged 65 and older by 2050, posing new challenges for healthcare systems. Frailty is associated with poorer prognosis, increased postoperative complications, and reduced treatment tolerance. Accurate frailty assessment (FA) is therefore crucial for diagnosis, risk stratification, and individualized treatment planning. Despite its clinical relevance, clear evidence-based guidance for implementation in gynecologic oncology remains lacking. Methods: An anonymous online survey with 51 multiple-choice and open-ended questions was conducted from May to August 2022. It targeted gynecologists and oncologists in Germany, Austria, and Switzerland, and was distributed to 633 healthcare institutions. Results: A total of 112 responses were analyzed, revealing considerable variation in the application of frailty assessments. Only 11% reported routine use, while 36% applied FA selectively. Screening tools varied: 52% used institution-specific forms, while validated instruments such as G8 or VES-13 were rarely used. Timing was inconsistent: 49% performed FA preoperatively, 36% before chemotherapy, 31% at first presentation, and 30% without a fixed timepoint. Prehabilitation programs were largely absent; only 21% of institutions offered them. 77% of respondents indicated a need for further training. Conclusion: There are substantial gaps in the use of frailty assessments in gynecologic oncology. Standardized procedures, prehabilitation programs, and targeted education are essential to improve care quality and treatment outcomes in the context of an aging patient population.


  • RETRACTED: Role of lymphadenectomy in advanced ovarian cancer—a subgroup analysis of the patients excluded from the LION trial (the Charité cohort)

    by Robert Armbrust, Christina Fotopoulou, Dario Zocholl, Radoslav Chekerov, Mustafa Zelal Muallem, Iona Braicu, Klaus Pietzner, Philipp Harter, Jalid Sehouli


  • Open Access

    The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey

    by Maximilian Riedel, Helene Herrmann, Thomas Bartl, Anna-Maria Rossner, Anna Tatzber, Chiara Flethe, Dario Zocholl, Barbara Schmalfeldt, Jalid Sehouli, Klaus Pietzner

    Background: The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria. Methods: We designed a questionnaire consisting of 34 items focused on physicans’ clinical experiences with ICIs and their management of irAEs. The survey was distributed between October 2022 and May 2023 to medical professionals with experience in the field of gynecologic oncology. Results: A total of 221 gynecologists participated in the study. Most respondents (n = 130, 59.1%) were primarily engaged in gynecologic oncology at the time of the survey, with an average of ten years of clinical experience. Individual experiences with regard to irAEs varied significantly. When asked which irAEs they had observed “frequently” or “very frequently”, respondents most commonly reported thyroiditis (37.2%), followed by skin reactions (23.6%), and pneumonitis (10.6%). A total of n = 16 (7.4%) reported at least one death of a patient due to irAEs. Feeling “unconfident” or “very unconfident” about managing irAEs was reported by 35.6% (n = 78). With regard to clinical management of adverse events after discontinuation of treatment, 32.4% (n = 68) ceased to inquire about irAEs after six months. Conclusion: The results of this survey provide valuable insights into physicians’ real-world experiences with irAEs associated with ICI treatment. Dealing with serious immune-related and potentially life-threatening side effects has become a routine aspect of clinical practice. Many physicians, however, express a lack of sufficient familiarity with irAEs and their management. Therefore, it is essential to improve medical education, specialized oncological training, and close interdisciplinary collaboration to improve patient care.

  • Open Access

    Ovarian cancer management in an ESGO ovarian cancer center of excellence: a systematic case study of the interprofessional and interdisciplinary interaction

    by David J. Krankenberg, Mustafa Zelal Muallem, Klaus Pietzner, Radoslav Chekerov, Robert Armbrust, Carmen Beteta, Wenzel Schöning, Marlene Lee, Julia Klews, Jalid Sehouli

    Purpose: With growing knowledge about ovarian cancer over the last decades, diagnosis, evaluation and treatment of ovarian cancer patients have become highly specialized, and an individually adapted approach should be made in each woman by interdisciplinary cooperation. The present study aims to show the variety and extent of medical specialties involved at our institution according to the European Society of Gynecologic Oncology (ESGO) Quality indicators (QI). Methods: A woman, diagnosed with high-grade ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) class IVb was selected for a single case observational study. The observation period (total = 22d) comprised preoperative diagnostic procedures, including imaging, the in-patient stay for cytoreductive surgery, and the postoperative course and case discussion at our interdisciplinary tumor board. Data were obtained by self-reporting and by patient file review. Results: Patient tracking demonstrated an interdisciplinary cooperation of 12 medical specialties [62 physicians (63% male, 37% female)], 8 different types of nursing staff [n = 59 (22% male, 78% female)], and 9 different types of perioperative/administrative staff (n = 23; male 17,4%, female n = 19, 82,6%). Contact with the patient was direct (n = 199; 76%) or without face-to-face interaction (n = 63; 24%). Conclusion: The present study demonstrates the high diversity of physicians and the affiliated medical staff, as well as interdisciplinary intersections within teams of a specialized hospital. Matching the ESGO QIs, this report underlines the requirement of an adequate infrastructure for the complex management of advanced ovarian cancer patients. Future prospective studies are warranted to evaluate the specific procedures and actions to optimize the interprofessional and interdisciplinary workflows.


  • Open Access

    Sexuality as a Prognostic Factor—Results of an Individual Patient Data NOGGO (North-Eastern German Society of Gynecological Oncology)-Meta-Analysis of 644 Recurrent Ovarian Cancer Patients Prior to Chemotherapy

    by Nicole Balint, Hannah Woopen, Rolf Richter, Adak Pirmorady-Sehouli, Klaus Pietzner, Jalid Sehouli

    Background: The aim of this study was to analyze the associations between sexuality, quality of life, treatment discontinuation, and survival in recurrent ovarian cancer (OC). Methods: Raw data from various phase II/III studies, including the questionnaires EORTC-QLQ-C30 and QLQ-OV28, were included. Data from the meta-analysis were calculated using logistic and Cox regression. Results: Data on sexuality were available for 644 patients. A total of 162 patients had an interest in sex and were sexually active (Group A). A total of 45 patients had an interest in sex and were sexually not active (Group I) and 437 patients had no interest in sex and were not sexually active (Group N). Group A was younger in median age (age at randomization), at 57 years, than Group I, at 60 years, and Group N, at 65 years (p < 0.001). Group A had a better ECOG performance status and fewer recurrences (all p < 0.001). FIGO stage, grading, and BMI were not associated with interest in sex and sexual activity. Group A showed higher scores in role, body, and social function (all p < 0.001), emotional functionality (p < 0.002), and body image (p = 0.012). In addition, Group A reported less pain, less peripheral neuropathy, and less fatigue (all p < 0.001). There was no association with the premature discontinuation of chemotherapy. Group A showed better survival rates compared to group N (22.3 months vs. 17.4 months, p < 0.001). Conclusions: Physicians should routinely address the topic of sexuality with ovarian cancer patients. Sexuality appears to be a marker for quality of life as well as overall survival.


  • Open Access

    Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO

    by Sabine Heublein, Joanna Baum, Anna Jaeger, Donata Grimm-Glang, Julia Olthoff, Elena Ioana Braicu, Osama Azzam Nieto, Kathrin Hassdenteufel, Barbara Schmalfeldt, Lars Hanker, et al.

    Background: Surgery is the backbone of early-stage ovarian cancer (OC) management. However, in practice, there is disagreement about the extent of surgical staging and whether additional adjuvant treatment should be provided. As omitting relevant diagnostic or therapeutic procedures might lead to undertreatment, we aimed to structurally investigate treatment practice in addition to prognostic factors in a multicentre series of patients (pts) diagnosed with early-stage OC. Patients: Within this retrospective, multicentre study, medical records of 379 pts who had undergone surgery for suspected early-stage OC between January 2014 and March 2020 were analysed. Results: Of the 379 patients, 292 had pT stage 1a-2a and had complete data on the extent of surgical staging. At least one surgical step was omitted in 100 pts (34.2%). Complete surgical staging (n = 192; (65.8%)) was more often performed in high-grade serous OC and was independent of the healthcare level of the hospital where the initial diagnosis was made. Missing to take peritoneal biopsies was associated with reduced relapse-free-survival in incompletely staged, pT1 cases (p = 0.03). About every second patient (46.7%) with a final stage lower than FIGO IIB and treated with adjuvant chemotherapy received combination chemotherapy. BRCA1 and BRCA2 testing was only performed in a subset of pts, and mutations were detected in 18% (14/79) and 9% (7/85) pts, respectively. Conclusions: This study helps to increase our understanding of early-stage OC treatment and prognosis. In addition to treating patients in compliance with current guidelines, the need for BRCA testing should also be considered for early-stage OC.


  • Open Access

    Real-World Evidence: How Long Do Our Patients Fast?—Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases

    by Maximilian Heinz Beck, Derya Balci-Hakimeh, Florian Scheuerecker, Charlotte Wallach, Hannah Lena Güngor, Marlene Lee, Ahmed Farouk Abdel-Kawi, Jacek Glajzer, Jekaterina Vasiljeva, Karol Kubiak, et al.

    Background: Despite the key role of optimized fasting in modern perioperative patient management, little current data exist on perioperative fasting intervals in routine clinical practice. Methods: In this multicenter prospective study, the length of pre- and postoperative fasting intervals was assessed with the use of a specifically developed questionnaire. Between 15 January 2021 and 31 May 2022, 924 gynecology patients were included, from 13 German gynecology departments. Results: On average, patients remained fasting for about three times as long as recommended for solid foods (17:02 ± 06:54 h) and about five times as long as recommended for clear fluids (9:21 ± 5:48 h). The average perioperative fasting interval exceeded one day (28:23 ± 14:02 h). Longer fasting intervals were observed before and after oncological or extensive procedures, while shorter preoperative fasting intervals were reported in the participating university hospitals. Smoking, treatment in a non-university hospital, an increased Charlson Comorbidity Index and extensive surgery were significant predictors of longer preoperative fasting from solid foods. In general, prolonged preoperative fasting was tolerated well and quality of patient information was perceived as good. Conclusion: Perioperative fasting intervals were drastically prolonged in this cohort of 924 gynecology patients. Our data indicate the need for better patient education about perioperative fasting.


  • Open Access

    Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)

    by Eva Roser, Philipp Harter, Dario Zocholl, Dominik Denschlag, Radoslav Chekerov, Pauline Wimberger, Christian Kurzeder, Annette Hasenburg, Mustafa-Zelal Muallem, Alexander Mustea, et al.

    Objective Gynecological sarcomas account for 3% of all gynecological malignancies and are associated with a poor prognosis. Due to the rarity and heterogeneity of gynecological sarcomas there is still no consensus on optimal therapeutic strategies. This study’s objective was to describe the treatment strategies used in patients with gynecological sarcomas in the primary course of disease. Methods The German prospective registry for gynecological sarcoma (REGSA) is the largest registry for gynecological sarcomas in Germany, Austria and Switzerland. Primary inclusion criteria for REGSA are histological diagnosis of sarcoma of the female genital tract, sarcoma of the breast or uterine smooth muscle tumors of uncertain malignant potential (STUMP). We evaluated data of the REGSA registry on therapeutic strategies used for primary treatment from August 2015 to February 2021. Results A total of 723 patients from 120 centers were included. Data on therapeutic strategies for primary treatment were available in 605 cases. Overall, 580 (95.9%) patients underwent primary surgery, 472 (81.4%) of whom underwent only hysterectomy. Morcellation was reported in 11.4% (n=54) of all hysterectomies. A total of 42.8% (n=202) had no further surgical interventions, whereas an additional salpingo-ophorectomy was performed in 54% (n=255) of patients. An additional lymphadenectomy was performed in 12.7% (n=60), an omentectomy in 9.5% (n=45) and intestinal resection in 6.1% (n=29) of all patients. Among 448 patients with available information, 21.4% (n=96) received chemo- or targeted therapies, more commonly as single-agent treatment than as drug combinations. Information about anti-hormonal treatment was available for 423 patients, among which 42 (9.9%) received anti-hormonal treatment, 23 (54.8%) of whom with low-grade endometrial stroma sarcomas. For radiotherapy, data of 437 patients were available, among which 29 (6.6%) patients underwent radiotherapy. Conclusion Our study showed that treatment of patients with gynecologic sarcomas is heterogeneous. Further trials are needed along with more information on treatment modalities, therapy response and patient-reported outcomes to implement new treatment strategies.


  • 2022-LBA-607-ESGO How long do our patients stay fasting? a multicentric prospective survey on the perioperative fasting in 924 Patients conducted by the JAGO study group

    by Maximilian Heinz Beck, Derya Balci-Hakimeh, Florian Scheuerecker, Charlotte Wallach, Hannah Wißbrock, Jens-Uwe Blohmer, Jalid Sehouli, Klaus Pietzner

    Introduction The optimization of perioperative fasting is a key step in increasingly established ERAS (extended recovery after surgery) concepts in (gynecologic) surgery. But only little data exists about actually observed fasting intervals before and after surgery in clinical routine. This prospective study of the JAGO (Young Academy of Gynecologic Oncology) and NOGGO e.V. investigates the length of perioperative fasting in a multicentric survey. Methods In 13 German gynecologic departments the length of pre- and postoperative fasting intervals were recorded by questionnaire. Furthermore, the patients‘ subjective condition, clinical history and experience and ideas about fasting were documented. Subgroup analyses were performed for benign and malignant indications, as well as for the extent of surgery. Results A total of 924 patients participated in the study. On average, patients did not eat for 17:02 h and did not drink for 9:21 h before surgery. The first postoperative meal was 9:42 h after surgery. Patients with malignant indications had significantly longer pre- (Δ=67 min) and postoperative (Δ=166 min) fasting intervals. Prolonged fasting intervals were also observed for patients with extensive surgery. In general patients felt well informed and the majority did not feel impaired by the adherence to fasting restrictions. Conclusions Patients fast significantly longer than recommended. Even more prolonged fasting intervals are observed in patients with malignant indications and extensive surgeries, where optimized fasting could play the greatest role. Therefore, better protocols on optimized perioperative fasting need to be implemented in routine clinical practice.